Hormone May Be Key to Long-Term
Weight Loss By LINDA A. JOHNSON (May
22)
- A hormone thought to boost appetite rises in the
bloodstream after dieters lose lots of weight, possibly explaining
why it's so hard to keep weight off long term - and offering a new
target for a diet drug, researchers say. Their small study of
severely obese people found much higher levels of a recently
discovered hormone made by stomach cells, ghrelin, in the blood
after the patients had lost significant weight. However, very
little ghrelin was in the blood of several people who lost weight
after gastric bypass surgery, an operation that sews shut 95 percent
of the stomach and reroutes the flow of food. "Not only did
(ghrelin levels) not go up, but in people who lost an enormous
amount of weight, it went way down,'' said Dr. David E. Cummings, an
endocrinologist who led the researchers at the University of
Washington and the Veterans Affairs Puget Sound Health Care
System. Cummings and Dr. Mitchell S. Roslin, chief of obesity
surgery at Lenox Hill Hospital in New York, say the abnormally low
ghrelin levels after gastric bypass could help explain why it is
more successful than dieting or operations that simply reduce
stomach size. Ghrelin is thought to be nature's way of making
people fatten up when food is plentiful to increase survival during
cycles of famine, a protective mechanism now harmful when plenty of
high-calorie food is available. The researchers and other experts
say the findings are circumstantial evidence of ghrelin's effects,
and more research is needed. The body has multiple backup systems
for regulating body weight, probably including other hormones not
yet discovered, said Dr. Stephen H. Schneider, director of diabetes
services at UMDNJ-Robert Wood Johnson Medical School in New
Brunswick, N.J. "This is probably one of a number of substances
which control appetite,'' and it's unclear how they interact, he
said. The study, reported in Thursday's edition of the New
England Journal of Medicine, involved patients who had sharply
reduced their weight and kept stable for three months. Five patients
who had gastric bypass surgery dropped from an average of 435 pounds
to 280 pounds, while 13 people on a supervised low-fat, liquid diet
dropped from an average weight of 220 pounds to 182 pounds. In
the diet group, ghrelin levels were consistently about 50 percent
higher after weight loss. Levels spiked before meals and plunged
after, both before and after weight loss. The bypass group had
barely detectable ghrelin levels and on average had 72 percent less
ghrelin than five dieters who ended up at about the same body mass
index, a ratio of weight to height. The bypass patients also had 77
percent less ghrelin on average than a comparison group of 10
normal-weight people. Some 75,000 to 100,000 severely obese
Americans are expected to undergo some type of bariatric, or
stomach-reducing, surgery this year. Gastric bypass is meant only
for people at least 100 pounds overweight. Ghrelin, discovered
about two years ago, has a role in promoting growth, from making
children taller to building bone density. Injecting the hormone
in rodents makes them eat right away, but ghrelin has not been
proven to stimulate appetite in people. Still, several major
pharmaceutical companies are trying to develop drugs to block the
hormone, Cummings said. "A true cure for obesity would be the
biggest moneymaker that any drug company's ever seen,'' he said.
AOL News Main, 05/22/02 17:00 EDT
Measurement of
circulating Ghrelin levels in fasting rat1 and human
obesity2 by Phoenix's Ghrelin RIA Kit have been published
in Nature and Diabetes.
Serum Ghrelin-ir in SD Rats: 1.26 ¡À0.14
ng/ml and the fasting SD Rats: 2.86 ¡À0.28 ng/ml
(non-extracted)1; Plasma Ghrelin-ir in lean Caucasians: 155 ¡À25 fmol/ml
and obese Caucasians: 106 ¡À23
fmol/ml2.
Extent and direction of ghrelin transport
across the blood brain barrier is determined by its unique primary
structure
Differential
transport of mouse ghrelin, des-octanoyl mouse ghrelin, and human
ghrelin across the blood-brain barrier in mice. Although
octanoylated (bioactive) mouse ghrelin crosses the mouse BBB
predominantly in the brain-to-blood direction, passage for
des-octanoyl mouse ghrelin was observed only in the blood-to-brain
direction. Human ghrelin, which differs from mouse ghrelin by two
amino residues only, was transported in both directions in mice. The
extent and direction in which the ghrelin can cross the BBB is
therefore influenced by at least two features of its primary
structure, its post-translationally added fatty acid side chain and
its amino acid sequence.
William A. Banks, Matthias
Tsch¡p, Sandra M. Robinson and Mark L. Heiman. THE
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS. Vol. 302,
Issue 2, 822-827, August 2002

Ghrelin enables the stimulation of growth
hormone release and control of energy balance. Kojima,M.
et al. Nature. 402, 656-660, 1999 Tsch¡p, M. et al. Nature. 407,
908-913, 2000 Nakazato, M. et al. Nature. 409, 194-198,
2001 Hosoda,H, et al. J Biol Chem (2000 May 8) Kojima, M, et
al. Nature 402,656-660 (1999) Wren A.M. et al, Endocrinology 141:
4325-4328, 2000
Biological Functions of Ghrelin

Effect
of intravenous injection of Ghrelin-[Dap] (Human)
on rat growth hormone release






© 2003-2004
Copyright Phoenix Pharmaceuticals, Inc. All Rights Reserved.
|